Parsons Ronald F, Locke Jayme E, Redfield Robert R, Roll Garrett R, Levine Matthew H
Emory University, Surgery Department, United States.
University of Alabama Birmingham, Surgery Department, United States.
Hum Immunol. 2017 Jan;78(1):30-36. doi: 10.1016/j.humimm.2016.10.009. Epub 2016 Oct 20.
Deceased donor kidney allocation was reorganized in the United States to address several problems, including the highly sensitized patients disadvantaged with large, diverse repertoires of antibodies. Here, five transplant surgeons review their center's experience with the new allocation changes: highlighting areas of accomplishment, opportunities for improvement and, in some cases, stark differences in practice. Across these five centers the highly sensitized patients (CPRA ⩾98%) range from 5.5 to 9.2% of the 12,364 candidates on their collective waitlist. All centers reported greater rates of kidney transplantations in highly sensitized patients (12.4-27%). Three of the programs (Emory, UCSF, UW) relied upon the virtual crossmatch prior to organ acceptance in a majority of cases (70-86%)-the mere presence of antibody on HLA antibody screen was sufficient to exclude the donor in most cases at Emory and UCSF. Penn and UAB relied upon the physical flow crossmatch in almost all cases prior to proceeding with transplantation. Current or historical donor-specific antibody was occasionally crossed in certain cases at UW and UAB necessitating IVIG/plasmapheresis and/or B cell depletion perioperatively. Some authors raised concerns for cost efficiency given the increased need for organ/specimen transportation, and extensive use of hospital resources and ancillary services. In general, we found that the new allocation system has successfully achieved one of its primary goals-increased kidney transplantation in the disadvantaged, highly sensitized patients; the long-term outcomes in all patients and the cost ramifications of these changes will require continued reassessment and clarification.
美国对已故捐赠者肾脏分配进行了重组,以解决几个问题,包括抗体种类繁多的高致敏患者处于不利地位。在此,五位移植外科医生回顾了他们中心在新分配变化方面的经验:突出成就领域、改进机会,以及在某些情况下实践中的明显差异。在这五个中心,高致敏患者(CPRA⩾98%)占其总等待名单上12364名候选人的5.5%至9.2%。所有中心报告称,高致敏患者的肾脏移植率更高(12.4 - 27%)。其中三个项目(埃默里大学、加州大学旧金山分校、华盛顿大学)在大多数情况下(70 - 86%)在接受器官前依赖虚拟交叉配型——在埃默里大学和加州大学旧金山分校,大多数情况下,仅HLA抗体筛查中存在抗体就足以排除该捐赠者。宾夕法尼亚大学和阿拉巴马大学在几乎所有情况下进行移植前都依赖物理流动交叉配型。华盛顿大学和阿拉巴马大学在某些情况下偶尔会交叉检测当前或既往的供者特异性抗体,这需要在围手术期使用静脉注射免疫球蛋白/血浆置换和/或B细胞清除疗法。一些作者对成本效益表示担忧,因为器官/标本运输需求增加,以及医院资源和辅助服务的广泛使用。总体而言,我们发现新的分配系统已成功实现其主要目标之一——增加了处于不利地位的高致敏患者的肾脏移植;所有患者的长期结果以及这些变化的成本影响将需要持续重新评估和阐明。